The FDA has approved a new blood test called Shield, developed by Guardant Health, to detect colorectal cancer in individuals aged 45 and older with average risk. This test does not replace colonoscopies, which are still recommended every 10 years, but it offers a less invasive option that could increase the number of people undergoing screening. Shield has a sensitivity rate of 83.1% and a specificity of 89.9%, although its ability to detect large polyps is limited compared to colonoscopies. Despite the risks of false negatives, the FDA believes the benefits of this test outweigh the risks, making it more accessible and covered by health insurance.
You can find the full news here:
https://abc7.com/post/la-fda-aprueba-analisis-de-sangre-para-detectar-cancer-de-colon/15122912